Cutaneous metastatic melanoma (CMM) and myelodysplastic syndromes (MDS) are two incurable cancers developing resistance to their reference antitumor treatments. Cells resistant to these therapies are characterized by a metabolic reprogramming which profoundly influences and promotes tumor progression. Therefore, inhibition of metabolic pathways...
-
July 7, 2020 (v1)PublicationUploaded on: December 4, 2022
-
January 17, 2017 (v1)Journal article
A series of nucleoside analogues bearing a 1,4,5-trisubstituted-1,2,3-triazole aglycone was synthesized using a straightforward click/electrophilic addition or click/oxidative coupling tandem procedures. SAR analysis, using cell culture assays, led to the discovery of a series of compounds belonging to the 5-alkynyl-1,2,3-triazole family that...
Uploaded on: February 28, 2023 -
February 16, 2018 (v1)Journal article
Polo-like kinases (Plks) define a highly conserved family of Ser/Thr kinases with crucial roles in the regulation of cell division. Here we show that Plk1 is cleaved by caspase 3, but not by other caspases in different hematopoietic cell lines treated with competitive inhibitors of the ATP-binding pocket of Plk1. Intriguingly, Plk1 was not...
Uploaded on: December 4, 2022 -
January 2021 (v1)Journal article
Abstract In the search of biguanide-derived molecules against melanoma, we have discovered and developed a series of bioactive products and identified the promising new compound CRO15. This molecule exerted anti-melanoma effects on cells lines and cells isolated from patients including the ones derived from tumors resistant to BRAF inhibitors....
Uploaded on: December 3, 2022 -
January 2021 (v1)Journal article
Abstract In the search of biguanide-derived molecules against melanoma, we have discovered and developed a series of bioactive products and identified the promising new compound CRO15. This molecule exerted anti-melanoma effects on cells lines and cells isolated from patients including the ones derived from tumors resistant to BRAF inhibitors....
Uploaded on: February 22, 2023 -
January 2021 (v1)Journal article
Abstract In the search of biguanide-derived molecules against melanoma, we have discovered and developed a series of bioactive products and identified the promising new compound CRO15. This molecule exerted anti-melanoma effects on cells lines and cells isolated from patients including the ones derived from tumors resistant to BRAF inhibitors....
Uploaded on: December 4, 2022 -
November 18, 2024 (v1)Publication
ABSTRACT MyeloDysplastic Syndromes (MDS) are a group of heterogeneous hematological disorders characterized by bone marrow failure and abnormal hematopoietic cell expansion, often progressing to acute myeloid leukemia (AML). Current treatments for AML and high-risk MDS have limited efficacy, requiring the exploration of new therapeutic...
Uploaded on: January 13, 2025 -
January 2020 (v1)Journal article
Myelodysplastic syndrome (MDS) defines a group of heterogeneous hematologic malignancies that often progresses to acute myeloid leukemia (AML). The leading treatment for high-risk MDS patients is azacitidine (Aza, Vidaza®), but a significant proportion of patients are refractory and all patients eventually relapse after an undefined time...
Uploaded on: October 14, 2023 -
July 15, 2021 (v1)Journal article
Abstract Overcoming acquired drug resistance is a primary challenge in cancer treatment. Notably, more than 50% of patients with BRAFV600E cutaneous metastatic melanoma (CMM) eventually develop resistance to BRAF inhibitors. Resistant cells undergo metabolic reprogramming that profoundly influences therapeutic response and promotes tumor...
Uploaded on: February 22, 2023 -
July 15, 2021 (v1)Journal article
Abstract Overcoming acquired drug resistance is a primary challenge in cancer treatment. Notably, more than 50% of patients with BRAFV600E cutaneous metastatic melanoma (CMM) eventually develop resistance to BRAF inhibitors. Resistant cells undergo metabolic reprogramming that profoundly influences therapeutic response and promotes tumor...
Uploaded on: December 4, 2022 -
July 15, 2021 (v1)Journal article
Abstract Overcoming acquired drug resistance is a primary challenge in cancer treatment. Notably, more than 50% of patients with BRAFV600E cutaneous metastatic melanoma (CMM) eventually develop resistance to BRAF inhibitors. Resistant cells undergo metabolic reprogramming that profoundly influences therapeutic response and promotes tumor...
Uploaded on: December 4, 2022 -
July 15, 2021 (v1)Journal article
Abstract Overcoming acquired drug resistance is a primary challenge in cancer treatment. Notably, more than 50% of patients with BRAFV600E cutaneous metastatic melanoma (CMM) eventually develop resistance to BRAF inhibitors. Resistant cells undergo metabolic reprogramming that profoundly influences therapeutic response and promotes tumor...
Uploaded on: February 22, 2023